InflaRx NV
IFRX
Company Profile
Business description
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Contact
Winzerlaer Strasse 2
Jena07745
DEUT: +49 3641508180
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
74
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,747.50 | 10.40 | -0.12% |
| CAC 40 | 7,656.12 | 27.61 | -0.36% |
| DAX 40 | 23,317.81 | 116.84 | -0.50% |
| Dow JONES (US) | 42,171.66 | 44.14 | -0.10% |
| FTSE 100 | 8,843.47 | 9.44 | 0.11% |
| HKSE | 23,269.81 | 440.88 | -1.86% |
| NASDAQ | 19,546.27 | 25.18 | 0.13% |
| Nikkei 225 | 38,637.94 | 247.21 | -0.64% |
| NZX 50 Index | 12,594.31 | 33.01 | -0.26% |
| S&P 500 | 5,980.87 | 1.85 | -0.03% |
| S&P/ASX 200 | 8,528.80 | 2.40 | -0.03% |
| SSE Composite Index | 3,359.78 | 29.03 | -0.86% |